FDA’s Purolea Warning Letter: A Paradigm Shift for AI in Regulated Manufacturing

Pharmacists analyzing tablet with digital pharmacy system

 By: Caitlin A. Koppenhaver, Attorney with Florida Healthcare Law Firm and Chief Industry Advisor to APA 

Purolea Cosmetics Lab – 722591 – 04/02/2026 | FDA

When AI Makes Compliance Look Better Than It Is: FDA’s Purolea Warning Letter Is a Wake-Up Call for cGMP Operations

FDA’s April 2, 2026 warning letter to Purolea Cosmetics Lab should get the attention of every manufacturer, quality leader, and compliance consultant working in regulated production. The letter is notable not just because FDA identified serious cGMP deficiencies, but because the Agency expressly addressed the company’s use of artificial intelligence in creating specifications, procedures, and master production or control records that were supposed to support FDA compliance. FDA’s message was clear: using AI to generate compliance documents does not relieve a firm of the obligation to ensure those documents are accurate, complete, and actually compliant with cGMP requirements.

That is the part of this warning letter that deserves broader industry attention. The problem was not simply that the company used AI. The problem was that the firm appeared to treat AI-generated materials as though they were a substitute for a functioning quality system. FDA stated that if AI is used as an aid in document creation, the output must be reviewed to ensure it is accurate and actually compliant with cGMP, and FDA tied that failure to 21 CFR 211.22(c). The Agency also documented what it described as overreliance on AI during manufacturing operations.

FDA then gave the kind of example that will likely be repeated in compliance discussions for some time. According to the letter, investigators found that the firm had not conducted process validation before distributing drug products, as required under 21 CFR 211.100. When that was raised during the inspection, the company reportedly responded that it did not know validation was required because the AI agent it used had not identified that requirement. FDA did not treat that as an excuse, but rather as evidence of a deficient system.

In a cGMP environment, the standard is not whether documents look sophisticated, organized, or professionally written. The standard is whether the firm’s methods, controls, procedures, and oversight actually operate in a way that satisfies Parts 210 and 211. In the same warning letter, FDA cited the company for failing to perform appropriate microbiological testing on finished product batches, failing to adequately test components for identity and conformity with specifications, failing to validate the reliability of supplier test analyses at appropriate intervals, and failing to ensure adequate quality unit oversight over manufacturing operations. The AI discussion appeared in the middle of those larger operational oversights, which is exactly the point: polished language cannot compensate for missing controls.

This is where some companies get into trouble. They assume that a set of procedures, batch templates, specifications, and quality forms that read well must also be compliant. But cGMP compliance is not a document aesthetics exercise. It is an operational discipline. A procedure is not protective just because it sounds credible. It has to reflect the actual process, assign responsibility correctly, require the right controls, and be followed in practice. A master record is not meaningful if it was copied, generated, or assembled without site-specific review. A quality system is not real if the quality unit is not exercising actual oversight over release, investigations, deviations, supplier qualification, validation, and change control. FDA’s own Quality Systems Approach guidance makes the same point in broader form: quality systems and risk management approaches can help manufacturers meet cGMP requirements, but they do not replace the underlying requirements in Parts 210 and 211.

The warning letter also reinforces why working with experienced compliance partners is so vital. FDA recommended that, before the firm pursues resolution of its compliance status, it should engage a qualified consultant under 21 CFR 211.34 to assist with meeting cGMP requirements, perform a comprehensive six-system audit, and evaluate the completion and effectiveness of corrective and preventive actions. That recommendation is important because it reflects FDA’s expectation that remediation must be substantive, not cosmetic. The right compliance partner is not there to hand over documents that sound sophisticated. The right partner helps ensure the procedures are legally and operationally sound, mapped to the actual manufacturing process, integrated into the firm’s quality system, and capable of standing up during inspection.

That is especially important now, when AI tools are becoming easier to use and easier to overtrust. AI can help organize information, accelerate drafting, and support internal workflows. But in a regulated manufacturing environment, those benefits only matter if they are paired with competent human review, independent quality unit oversight, and site-specific implementation. Otherwise, the technology can create a dangerous illusion of compliance: documents that look complete, systems that appear mature, and records that seem polished, while the underlying controls are incomplete, misunderstood, or absent. FDA’s Purolea letter is a reminder that the Agency inspects how a system functions, not how well it reads.

The real lesson here is simple. Compliance has to be operative. It has to live in the training, the batch review process, the validation program, the raw material controls, the microbiological safeguards, the quality unit’s decisions, and the data that support release. If AI is used anywhere in that process, it must remain a tool, not the decision-maker. And if outside consultants are involved, their role should be to help build a system that works in practice, not just one that looks impressive in a binder.

The same point extends beyond cGMP and beyond AI. Across healthcare compliance more broadly, a policy, consent form, SOP, training module, audit framework, or marketing review process is not protective simply because it sounds polished, sophisticated, or legally informed. In regulated settings, the real question is whether the measure is accurate, operationalized and aligned with the actual legal and regulatory requirements that apply to the business. FDA’s criticism in the Purolea letter reinforces that appearance is not the standard, operational compliance is.

Healthcare M&A Trends in 2026: A Shift in Focus Toward Dermatology

rejuvenating facial treatment

As we move through the first quarter of 2026, the healthcare acquisition landscape is showing a clear divergence across specialties. While deal activity remains active overall, not all sectors are participating equally. In fact, we are seeing a notable pause in certain areas—alongside strong momentum in others.

Headwinds in Primary Care and Pediatrics

Primary care and pediatric practices are currently facing increased scrutiny from both buyers and lenders. The primary driver behind this hesitation is reimbursement uncertainty.

Ongoing payer cuts and evolving reimbursement methodologies—particularly those tied to government programs—have introduced a level of unpredictability that investors are not comfortable underwriting at this time. In Florida specifically, the Agency for Healthcare Administration (AHCA) is still working through payment-related issues, further contributing to market hesitation.

As a result:

  • Valuation multiples in these sectors have softened 
  • Many deals are being delayed or paused entirely 
  • Buyers are taking a “wait-and-see” approach until reimbursement stabilizes 

This doesn’t mean these businesses lack long-term value—but in the current environment, uncertainty is suppressing transaction activity.

Dermatology Emerges as a Standout Performer

On the other end of the spectrum, dermatology has become one of the most attractive sectors in healthcare M&A.

We are seeing strong demand from private equity-backed groups actively pursuing acquisitions in:

  • Traditional insurance-based dermatology practices 
  • Hybrid models that include med spa or aesthetic components 

What makes dermatology particularly compelling right now:

  • Favorable reimbursement dynamics compared to primary care 
  • Strong cash-pay components (especially in aesthetic services) 
  • High margins and scalable service lines 
  • Operational flexibility across different business models 

Interestingly, size is not the primary driver of value in this space at the moment. Both small and mid-sized practices are commanding strong interest and, in many cases, higher valuation multiples than we’ve seen historically.

Why Some Practices Command Premium Valuations

Across all specialties—but especially in dermatology—there is a consistent theme among practices achieving the best outcomes in a sale:

Preparation and operational discipline matter.

Buyers are paying a premium for businesses that demonstrate:

  • A strong culture of compliance 
  • Clean, well-organized financials 
  • Accurate and defensible profit and loss statements 
  • Consistent and transparent tax reporting 

When these elements are in place, the transaction process becomes significantly smoother. More importantly, it reduces perceived risk for buyers—which directly translates into higher and more achievable purchase prices.

Deal Structures: Roll-Ups vs. Strategic Acquisitions

We are also seeing a mix of transaction structures in today’s market:

  1. Roll-Up Strategies: Private equity-backed platforms are continuing to aggregate practices, particularly in dermatology. These models focus on integration, operational efficiency, and scaling regional or national footprints. 
  2. Outright Acquisitions: Strategic buyers and larger platforms are also executing full buyouts, especially when targeting high-performing or well-positioned practices. 

Each structure comes with different implications for physicians—particularly around autonomy, equity rollover, and long-term upside—making deal structuring just as important as valuation.

Looking Ahead

The current M&A environment in healthcare is not slowing—it’s shifting.

  • Sectors tied heavily to reimbursement uncertainty are experiencing temporary slowdowns 
  • Specialties with diversified revenue streams and strong margins are accelerating 

For practice owners, this creates both a cautionary signal and an opportunity:

  • Timing matters more than ever 
  • Positioning your business correctly can significantly impact valuation 
  • Being prepared operationally is no longer optional—it’s essential 

As 2026 unfolds, we expect continued momentum in dermatology and similar specialties, while reimbursement clarity will be the key factor in unlocking stalled segments like primary care and pediatrics.

Not Anti-Regulation, Just Better Regulation: Florida MedSpa Bill (HB 1429) Dies in Committee

MedSpa staff reviewing medical form

By: Caitlin A. Koppenhaver

Florida’s effort to create a new licensure framework for medical spas has come to an end for the 2026 legislative session. HB 1429, which would have established a new Board of Pharmacy-driven oversight structure for certain medical spa operations, last saw action on March 13, 2026, when it died in the House Health Professions & Programs Subcommittee.

That is a welcome result, and not because the medical spa and wellness space should exist without oversight.

Our earlier article explained that HB 1429 would have created the Medical Spa Prescription Drug Oversight Act, placing a broad range of medspa activities into a new Board of Pharmacy-centered licensing structure. As written, the bill was not limited to one narrow practice model or one isolated concern. It was expansive enough to touch businesses involved in weight-loss services, hormone therapy, longevity care, botulinum toxin treatments, IV therapies, and other wellness services involving prescription products.

The concern was never whether Florida should promote patient safety and accountability in this area. Those goals are important, and they are shared across the healthcare industry. Medical spas, pharmacies, and other healthcare participants operate in a setting that involves prescribing, supervision, drug handling, advertising, documentation, and professional responsibility. Meaningful regulation has an important role in supporting those objectives.

The more difficult question was whether this particular bill was the right fit for the industry as it exists today.

Florida already has an established regulatory framework in this space. Physicians, physician assistants, nurse practitioners, pharmacists, pharmacies, and other licensed professionals are already governed by licensure laws, scope-of-practice rules, prescribing requirements, delegation standards, and disciplinary oversight. Consumer protection laws also remain in play. In addition to those standards, HB 1429 would have added another layer, this time at the facility level, under a pharmacy-oriented model that may have been appropriate for some circumstances, but not necessarily for the full range of businesses that could have been swept in.

That is why the bill’s failure should not be read as opposition to regulation. It is better understood as recognition that regulation is most effective when it is closely tailored to the specific concerns it is intended to address.

If there are particular concerns about unsafe prescribing, insufficient supervision, improper storage or handling of drugs, misleading marketing, or poor documentation, those issues can and should be addressed directly. But a bill that casts a very wide net across an already regulated and highly varied industry can create burden without enough precision. When that happens, the law can begin to function less like a targeted public-safety measure and more like a broad structural framework.

That concern was especially pronounced here because Florida already has tools to investigate and respond to misconduct. Businesses that cut corners, misstate services, prescribe inappropriately, or otherwise fall short of legal requirements are not operating in a vacuum. Existing law already gives regulators multiple avenues to review and discipline that conduct.

It is important to keep in mind that none of this means the industry gets a pass. Medspas and wellness businesses in Florida still need to pay close attention to how they are structured, how services are provided, who is prescribing, who is administering, how products are sourced and handled, what their marketing says, and how records are maintained. Those obligations did not disappear because HB 1429 died.

Still, the bill’s failure leaves Florida in a better position than a hurried or overinclusive licensing scheme would have. It preserves room for a more thoughtful legislative approach in the future, one that is narrower, more deliberate, and better matched to the specific risks lawmakers may want to address.

That is why this outcome should be viewed positively. Not because oversight is unnecessary, but because broad new regulation is not always the best form of regulation, particularly where a substantial body of existing law is already in place.

Florida RN Renewal Guide (2026): Requirements, Deadlines, CE Credits, and Common Mistakes

Florida RN license

Renewing your Florida RN license can be simple and stress-free. This complete guide helps registered nurses understand Florida RN renewal requirements, CE hours, deadlines, fees, and the online renewal process—so you can stay compliant, confident, and focused on your nursing career with total peace of mind.

Continue reading

Attorney Jeff Cohen: Leading Legal Advocate for Justice & Results

Attorney Jeff Cohen

Discover the remarkable career of Attorney Jeff Cohen, a trusted Florida legal expert known for his success in personal injury, civil litigation, and business disputes. With a client-first approach and a commitment to justice, Cohen’s work not only achieves results but also sets a standard of excellence in the legal profession.

Continue reading

Is Your Business Structure Holding You Back?

Team brainstorming project plans with charts

As companies grow, revenue increases, teams expand, and the vision of success becomes reality. However, this success can also expose foundational issues if the original legal and operational structure no longer aligns with the evolving needs of the business. Many founders discover that what once worked is now creating friction, limiting opportunities, and introducing new risks.

This is a common crossroads in a business’s development: realizing that the initial setup is now a barrier to achieving future goals. At this point, corporate restructuring becomes not just prudent, but essential. This process should not be viewed as a sign of failure, but as a strategic evolution to meet both current challenges and long-term aspirations. Whether planning an exit, managing the complexities of rapid growth, or bringing on new partners, adapting the business structure is critical for securing future success.

For many entrepreneurs, building a scalable and sellable company is a key objective. Planning for an exit should influence strategic decisions from the earliest stages. Yet, founders often become so immersed in the daily demands of the business that the corporate structure is overlooked, making the eventual sale more challenging.

Buyers are drawn to businesses with clear, transparent structures. Assets, liabilities, ownership interests, and intellectual property should all be straightforward and well documented. A tangled or outdated structure can delay or even derail negotiations, frequently resulting in a reduced valuation. For instance, companies operating as sole proprietorships or simple LLCs with commingled personal and business finances present unnecessary risk to acquirers.

Working with a healthcare business attorney, founders can prepare by creating a “clean room” environment: organizing financials, clarifying ownership, ensuring contracts are current, and securing intellectual property within the right entity. Taking these actions early not only streamlines the exit process, but also significantly enhances the value and appeal of the business.

Fast-growing businesses often start with the simplest legal structures to minimize costs and move quickly. While practical in the beginning, this approach can become unsustainable as an organization’s size and complexity increase.

Lack of clarity around roles, responsibilities, and ownership can result in serious operational headaches. Ambiguity regarding the ownership of intellectual property or decision-making authority leads to internal friction and inefficiencies as companies expand. Formal structures that define these relationships are essential for maintaining control and operational excellence.

Emerging healthcare and life sciences sectors, such as peptides, present additional regulatory challenges. Changing regulations can introduce significant risk to companies not structured to isolate liabilities. In these cases, a thoughtful restructuring plan—such as “siloing” business units into separate legal entities under a parent company—can provide crucial protection. With expert legal guidance, risk is contained so that setbacks in one unit do not threaten the entire enterprise. This approach enhances resilience and supports agile responses to shifting legal or market landscapes.

The original choice of corporate entity directly affects the ability to attract capital and add key partners. Structures that once served the business well may now limit fundraising and collaboration opportunities.

For example, the S Corporation (S-corp) is popular for small business tax advantages but imposes strict limits on the number and type of shareholders. Only one class of stock is permitted, and ownership is limited largely to U.S. citizens or residents. This restricts the ability to create varied investment opportunities, such as preferred stock for venture capitalists or equity incentives for executives.

Restructuring, often through conversion to a C Corporation, opens the door to a wider range of investors and partners. C-corps allow multiple classes of shares, facilitating the participation of venture capital, strategic partners, and top-tier talent. Legal professionals specializing in healthcare business law can guide founders through the process, ensuring the transition aligns with strategic growth plans and industry regulations.

Corporate restructuring is a natural stage in a company’s journey. Early decisions made for speed or simplicity often require reexamination as the business matures. Ongoing assessment and adjustment of the corporate framework allow organizations to capitalize on opportunity, minimize risk, and pave the way for sustainable growth.

Engaging a healthcare business attorney can make the process smoother and more effective. Expert guidance helps founders anticipate challenges, avoid common pitfalls, and position businesses for both immediate needs and long-term goals.

For founders who recognize their structure may be holding the company back, now is the time to seek professional guidance. A proactive approach to corporate restructuring will not only resolve current limitations but also prepare the organization to seize future opportunities in a dynamic healthcare market.

Unique Issues for Licensed Clinicians Prescribing Compounded Peptides

Doctor writing in notebook prescribing peptides

By: Jeff Cohen

The use of compounded peptides, particularly GLPs (glucagon-like peptides), presents a complex and nuanced landscape for licensed clinicians. While these treatments offer potential benefits, they are not without risks. Clinicians must navigate a web of regulatory, legal, and ethical challenges, including:

  1. FDA Shortage Declarations and Reversals
    The FDA’s declared shortage of GLPs initially opened the door for the compounded GLP industry. However, in the fall of 2024, the FDA announced the shortage had ended, signaling its intent to curtail the use of compounded GLPs.
  2. Regulatory Pushback on Specific Compounded Peptides
    The FDA has actively urged state medical boards to restrict clinicians from using compounded peptides like retratrutide and cargrilintide.
  3. Legal Actions by Pharmaceutical Giants
    Major pharmaceutical companies, including Eli Lilly and Novo Nordisk, have filed lawsuits against clinical enterprises utilizing compounded GLPs, further complicating the legal landscape.
  4. FDA Category 2 Bulk Drug Substances
    Many popular compounded peptides, such as AOD, BPC-157, and Epitalon, are listed on the FDA’s Category 2 bulk drug substances list, marking them as “suspect” chemicals.
  5. State-Level Regulatory Scrutiny
    Some state regulators are actively investigating and pursuing clinicians who use or recommend compounded peptides, adding another layer of risk.

Licensed clinicians face heightened exposure to these issues simply by virtue of their professional licensure. To navigate this challenging environment, they must take proactive steps to understand and mitigate their risks. Key measures include:

A. Understanding the Legal and Regulatory Landscape
Clinicians should engage in thorough discussions to fully grasp the laws, options, and risks—not just those related to the FDA but also state-level regulations and broader legal implications.

B. Ensuring Comprehensive Professional Liability Coverage
It’s critical to confirm that professional liability insurance includes regulatory defense, not just medical malpractice coverage. The use of compounded peptides can attract scrutiny from both state and federal regulators.

C. Utilizing Tailored Informed Consent
Clinicians should employ highly specific, well-crafted informed consent documents tailored to the peptides they recommend. These documents should clearly outline the risks and regulatory status of the treatments.

D. Verifying Product Quality
Unlike FDA-approved branded products, compounded peptides lack the same level of regulatory oversight. Clinicians must ensure the quality of the products they use and be prepared to counter the perception that their use of compounded products is driven by financial motives.

E. Maintaining Clinical Leadership
Above all, clinicians must apply the same rigorous clinical leadership to the use of compounded peptides as they do to every patient encounter. This includes proper diagnosis, prescribing, treatment, and documentation.

Clinicians interested in prescribing compounded peptides must dedicate the time and effort to thoroughly investigate the associated liability and regulatory nuances. By doing so, they can make informed decisions and implement strategies to mitigate risks. As the old adage goes: Measure twice, cut once.

Breaking Up with Your Employer: What Physicians Need to Know About Terminating Employment Agreements

Handshake over employment agreement contract

By: Michelle Caputi

Ending a physician employment agreement is a significant decision that requires careful planning and attention to detail. Whether you’re moving on to a new opportunity, stepping away from clinical practice, or simply seeking a better fit, the way you handle your termination can have lasting effects on your career, reputation, and relationships within the medical community.

Step 1: Review the Termination Provisions

The first step in terminating your physician employment agreement is to carefully review the termination provisions in your contract. These provisions outline the rules and requirements for ending the agreement, including:

· Termination for Cause vs. Without Cause: Most physician contracts allow for termination either “for cause” or “without cause.” Terminating for cause typically involves specific reasons outlined in the contract, such as misconduct or breach of duties. However, this can have serious implications for your future employment and references. Terminating without cause is often the safer route, but it’s important to consult with a healthcare attorney to determine the best approach for your situation.

· Notice Period: Many contracts require a specific notice period before termination. This could range from 30 to 120 days or more. Failing to provide proper notice could result in financial penalties or legal disputes.

Step 2: Understand the Notice Requirements

Once you’ve reviewed the termination provisions, it’s time to focus on the notice requirements. Pay close attention to:

· How to Provide Notice: Your contract may specify how notice must be given—whether it’s in writing, via certified mail, or through another method. Following these instructions to the letter is critical to ensure your termination is valid.

· Timing: Make sure you provide notice within the required timeframe. If you’re planning to terminate without cause, giving ample notice can help maintain goodwill and ensure a smoother transition.

Step 3: Check for Non-Compete Provisions

Non-compete provisions, also known as restrictive covenants, are common in physician employment agreements. These clauses may limit your ability to practice within a certain

geographic area or timeframe after leaving your current employer. Before terminating your agreement, review the non-compete language carefully to understand:

· Scope and Duration: How far does the restriction extend, and for how long? Are there exceptions for certain types of practice or locations?

· Enforceability: Non-compete clauses are subject to state laws, and their enforceability can vary widely. A healthcare attorney can help you assess whether your non-compete is likely to hold up in court.

Step 4: Evaluate Tail Coverage

Tail coverage is a critical consideration when terminating a physician employment agreement. This type of insurance provides protection against malpractice claims that arise after you leave your employer but are related to incidents that occurred during your employment. Key questions to ask include:

· Who Pays for Tail Coverage? Some contracts require the employer to cover the cost, while others place the responsibility on the physician.

· What Are the Costs? Tail coverage can be expensive, so it’s important to budget for this expense if you’re responsible for it.

Step 5: Review Indemnification Language

Indemnification clauses outline how liability is handled during your employment. Before terminating your agreement, review this language to understand:

· Your Coverage: Were you adequately protected during the course of your employment? Are there any lingering liabilities you need to address?

· Post-Termination Obligations: Does the indemnification clause impose any obligations on you after you leave?

Step 6: Consider the Impact of Termination

Terminating your employment agreement is not just a legal and financial decision—it’s also a professional and relational one. Consider the following:

· Future Employment and References: Terminating for cause can raise red flags for future employers and may impact your ability to secure positive references. Whenever possible, lean toward terminating without cause to preserve your professional reputation.

· Community Relationships: Maintaining positive relationships with facilities, medical staff, and colleagues is essential, especially if you plan to continue practicing in the same area. A respectful and professional approach to termination can go a long way in preserving these connections.

Step 7: Consult with a Healthcare Attorney

Terminating a physician employment agreement is a complex process with significant legal and professional implications. Consulting with a healthcare attorney can help you:

· Understand your rights and obligations under the contract.

· Navigate the termination process smoothly and avoid potential disputes.

· Protect your career, reputation, and financial interests.

Ending a physician employment agreement is never a decision to take lightly, but with careful planning and the right guidance, it can be a positive step forward in your career. By reviewing your contract, understanding your obligations, and seeking legal advice, you can ensure a smooth transition and set yourself up for success in your next chapter.

Florida’s CHOICE Act: A New Era for Noncompete and Garden Leave Agreements

Doctor consulting patient at laptop

By: Caitlin A. Koppenhaver

Effective July 1, 2025, Florida’s CHOICE Act (Contracts Honoring Opportunity, Investment, Confidentiality, and Economic Growth) significantly expands the enforceability of noncompete and garden leave agreements, making Florida one of the most employer-friendly states in the country for restrictive covenant enforcement.

Who Is Covered?
The law applies to employees and independent contractors earning more than twice the average annual wage in their Florida county of residence or the employer’s principal place of business. Healthcare practitioners are specifically excluded. Both Florida-based employers and out-of-state companies with Florida employees may fall under the Act.

Noncompete Agreements
Covered noncompete agreements can restrict a former employee from working in a similar role or using confidential information for up to four years after employment ends. To be enforceable, the agreement must be in writing, provided at least seven days before the offer to enter into an employment agreement expires, and must inform the employee of their right to seek legal counsel before execution of the agreement. The employee must also acknowledge they will have access to confidential information or customer relationships.

Garden Leave Agreements

Garden leave provisions allow an employer to require advance notice of resignation up to four yearsduring which the employee remains on payroll with full salary and benefits. The employee is only obligated to work for the first 90 days of that notice period. Similar procedural requirements apply as with noncompetes.

Enforcement
The CHOICE Act presumes these agreements are enforceable. Courts are required to issue injunctions unless the employee proves, by clear and convincing evidence, that their new role will not involve unfair competition or misuse of confidential information, or that the employer failed to uphold their payment obligations during the garden leave period.

What This Means for Employers and Employees

Employers should review and update their agreements to comply with the CHOICE Act’s requirements. Employees entering into these agreements should understand the legal obligations they are assuming, as these restrictions may significantly impact future employment opportunities.

Florida Health Care Providers: Don’t Miss the New Background Check Rule Starting July 1, 2025

Healthcare provider reviewing background check document

By: Caitlin A. Koppenhaver

“Cleared to Care” Campaign Helps You Stay Compliant and Licensed

If you’re a licensed health care provider in Florida, there’s a big change coming your way. Florida’s House Bill 975 (HB 975), which became law effective July 1st, 2025 requires most licensed providers to complete a background screening when applying for or renewing their individual licensure. Staying compliant with the new law is mandatory to maintain licensure. To help licensed providers comply and prepare, the state has launched a “Cleared to Care” campaign.

Who Needs to Do This?

Most licensed health care professionals in Florida will be affected, including doctors, nurses, therapists, and more. However, there are a few exemptions. Emergency medical technicians, paramedics, pharmacy interns, registered pharmacy technicians, and radiologic technicians are exempt unless applying through the military active-duty spouse licensure pathway. Fingerprint retention requirements do not apply to these professions. 

What You Need to Know

This isn’t just a routine update. If you delay the screening process, your license application or renewal could be delayed or expired. Because fingerprinting and processing may take time, especially since this has become a requirement for most licensed healthcare professions, it’s important to complete this step as soon as possible.

For License Renewals

You can start renewing 90 days before your license expires. It’s best to get your fingerprinting completed as soon as possible to avoid delays in obtaining or renewing your Florida license.

For New Applicants

You must complete the background screening as part of your application. Don’t wait until the last minute. There are also resources for out-of-state applicants to complete this step.

Act Now, Don’t Risk Losing Your License

With thousands of practitioners needing to comply, waiting until the last minute is risky. Start your background screening early to avoid delays or interruptions in your ability to practice. 

Additional Resources:

Florida’s Cleared to Care Campaign: 205.03.25-ClearedtoCare-Poster.pdf

Background Screening Steps and FAQ: Initiate a Screening – FL HealthSource • Health Care Resources for Consumers & Providers